What’s News in Earnings: How Big Pharma Is Expanding the GLP-1 Market
Bonus Episode for May 8. Financial results from pharmaceutical companies Eli Lilly, Novo Nordisk, Merck, Bristol Myers Squibb and AbbVie show strong demand continuing for weight-loss drugs and autoimmune treatments. Wall Street Journal pharma reporter Peter Loftus discusses which drugmakers have the upper hand in the…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from WSJ What’s News
See all episodes →Similar episodes from other shows
More like WSJ What’s News →
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Different Reads On The Consumer… And Pharma’s Obesity Drug Price Negotiations 11/5/25
A New Name in Weight-Loss Drugs
Novo Nordisk, Eli Lilly and the GLP-1 economy
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.